https://www.targetedonc.com/view/emerging-frontiers-in-immunotherapy-the-promise-of-nk-cell-therapies
We got a mention.
The phase 1b ADVENT-AML trial is exploring the use of allogeneic NK cells in combination with azacitidine and venetoclax (Venclexta) in patients with newly diagnosed AML (NCT05834244). The synergy of the regimen allows for upregulation of silenced NKG2D ligands, priming of leukemia cells, and reduction of disease burden.17
- Forums
- ASX - By Stock
- Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
https://www.targetedonc.com/view/emerging-frontiers-in-immunother...
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $23.12M |
Open | High | Low | Value | Volume |
2.9¢ | 2.9¢ | 2.7¢ | $14.49K | 518.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1378548 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 158093 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1378548 | 0.027 |
6 | 812615 | 0.026 |
6 | 910000 | 0.025 |
10 | 1506666 | 0.024 |
9 | 2772007 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 158093 | 2 |
0.029 | 25624 | 1 |
0.030 | 221388 | 3 |
0.031 | 451071 | 4 |
0.032 | 1550000 | 3 |
Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
2.8¢ |
  |
Change
-0.002 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
2.8¢ | 2.8¢ | 2.8¢ | 252061 | ||
Last updated 15.47pm 06/05/2024 ? |
Featured News
CHM (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online